Software Medicine, patented.

---

Development of process improving products for education and hospitals and prior experiences has been a driving force for thorough research in this area. Experiences from elderly care, extensive field trips and research in health care and hospital environments have contributed to this invention. Also, discussions with elderly care institutions and with other comparables about existing products and need accompanied by the many budgetary constraints of today have formed this product. Software Medicine is mentioned as “a key player in the Global Home Health Care Software Market, Key Players” by Verified market research intelligence. Further, Software Medicine & Store Tools, Strategies has been successful this year and has gone on to receive... Global Medicine Software Provider of the Year 2023 by Global Health and Pharma. Award link, press.  

---

---

Investors, ESG is realised with Software Medicine. Maximizing return but also Sustainably, Socially responsible and with Impact.

A few important points with the software medicine and recent listings and other products marketed.

- The software medicine fills the 8P's very well. 8P's for profits from Blockbusters: Patient need, Price premium, Payers Coverage, Promotion Aggressive, Prescription Volume, Production Costs Low, Purchasers Acceptance, Provider Acceptance. The 8P's for blockbusters describes requirements for a product that achieves a sales level of $1 billion per year in big pharmaceutical companies.

- Device is class MD 1 and is CE marked when brought to market.

- A vast number of researches of the device functions operation and bettering effect enable the classification and CE marking.

- The CER cites 240 clinical researches that prove that Software medicine functions offer its user group relief and solutions for all the functions investigated including lower cost and income. Further clinical research prove that age, gender, situation, and location are not a factor for Software medicine function effect. No contraindications or side effects were reported in any of the researches concerning any of the Software medicines functions.

- MD1 class in non-invasive, whereas MD2- is. I.e. something is inserted into the human body. The functions, according to the research, are not harmful for man.

- Extensively researched and widely concurred effects. (USA, EU, Asia, etc.) E.g. Most doctors in Britain see between 1 and 5 patients a day due to isolation. Software medicine is effective for this in its environment. Britain has appointed a minister for loneliness.

- The device combats isolation, exclusion and psychiatric disorders. Psychiatric disorders account for 22,8% of the global burden of diseases, largely driven by population growth and ageing. With an estimated 350 million people affected globally, the economic burden of depressive disorders in the USA alone has been estimated to be more than US$210 billion, with approximately 45% attributable to direct costs, 5% to suicide-related costs, and 50% to workplace costs. Antidepressants are widely used treatments for major depressive disorder, which are available worldwide. However, there is a long-lasting debate and concern about their efficacy and effectiveness, because short-term benefits are, on average, modest; and because long-term balance of benefits and harms is often understudied.

- Its function has improved quality of life by 15% over 6 months. Its function has increased survival over 1 year by 6,5%.

- Software Medicine functions after stroke not only enhances behavioural recovery, but also induces fine-grained neuroanatomical changes in the recovering brain.

- FDA classification is not exactly the same but similar and lighter for MD1 CE type devices. Research performed elsewhere is valid with the FDA. (Separate researches are not needed.) Japan is automatic after the CE mark. After the FDA Russia is more a formality. Russia enables India. China has separate requirements. Although it is good to note the non-invasiveness and thus lighter requirements.

- Other important factors are automatic function. The device does not require personnel resources to function. As we know these resources can be stretched.

- The personnel can use the device for their benefit as well in healing and servicing the patient. This can happen for example in therapy where it functions very well.

- The device can function as a process improver around daily issues in an institution. This can be made automatic depending on the institution and its needs. (E.g. The RFI from the major hospital.)

- The use environment is after procedure at hospitals. In geriatric and home care. The research and good results cover the world. Language or other country barriers do not exist. Given the above-mentioned certifications.

- Insurance deductibility is a good thing.

- Reduction of costs from direct use and with regards to the patient are good as well making the overall utility created positive. Healing, wellbeing and bettering effects are vastly proven.

Recent comparables and benchmarks. 1st more local companies and then a US and global peer group. "The Peer group is the most important, Nasdaq + originating investment banks and legal firms." 

- One of the top hospitals in the world (US) has posted a RFI for 100-500K per year for the other cost saving part of the devices functions. The problem tackled is a costly one. The cost in the US is estimated to be $26 billion per year, of which $17 billion is considered preventable. This cost or reductions of it have not been included in Software software medicine utility numbers.

 - Strategies Software medicine has many pros, medicine also for pain, deductible, cost saving, unique, patented, large market, the CER +240 clinical researches prove all function effects without contraindications.

 - Senzime share price has risen from 7,5 to 15 in the last months of 2019(+100%) as US is now a potential market. This is for a patient monitoring system. They have some sales, 50 units, in Korea where also education and instruction of their distributor’s sales force is underway and a bit of sales in Europe (CE mark). The product works and as it is Class II or III the FDA approval is important, harder and costlier to get. Value is about SEK800mil 21.10.2019 with half year results at SEK -9.1 mil. Local distributors will start selling in 2020.

Strategies, Software medicine is a pain reducing, healing and cost cutting product, Class1, with effects proven in +240 researches in the CER without contraindications. Markets are the same with CE, applicable, and FDA fileable. Automatic device for staff. Local distributors. 

 - Kaia Health has raised $10 mil. for its motion technology to help manage pain — it is cheaper than prescription drugs. Kaia has empirical evidence on its side: In a clinical study conducted at the Technical University of Munich’s Centre for Pain Therapy in Germany, the start-up’s app-based approach reduced lower back pain by 40 percent. Kaia Health raised $10 million after a $4 million in June 2016.Total to $14 million and will be used to fund further clinical studies. Reimbursement deals with German health insurance companies, including Barmer, Germany’s largest health insurance company, make them available at no charge. Self-service meditation apps and services are all the rage lately. There’s Simple Habit, which competes with Headspace, Pause, Calm, Shine, BioBeats, and Digg cofounder Kevin Rose’s Oak — a few of which have a significant funding advantage. Calm raised $27 million at a $250 million valuation in June, while Headspace brought in a $37 million round last summer. “Despite prowess for fundraising, few have been clinically validated, pointed out Dr Mani Rafii, who sits on Barmer’s board.”

 - VirtaHealth Coach Software tool for remote monitoring and analysis of patients for doctors pays off. Their 1st study shows good results with diabetes 2. 82$ million raised in a few months for partly Finnish (US based) VirtaHealth Coach that can reverse type 2 diabetes. Virta unveiled its technology last year, along with $37 million in funding. Virta Health, a startup that is taking a software approach to treating diabetes rather than pills or injections, has raised an additional $45 million in funding to support its technology. Virta Health, the first company with a clinically-proven treatment to safely and sustainably reverse type 2 diabetes and other chronic metabolic diseases without the use of medications or surgery.

 - Recently Nasdaq listed BBS 2.2018 (Artebone) Artebone is an invasive syringe and substance, thus classification requirements are harder. It is a medical device. Vision BBS-Bioactive Bone Substitutes Plc’s vision is to be one of the leading international companies in the field of bioactive implants (orthobiological products), with the aim of dealing with various types of orthopaedic damages and bone healing problems. IPO, Company accepted subscriptions on 20th February 2018.The company has no turnover. Company is approximately EUR 28 million immediately following the IPO. BBS will receive gross proceeds of approximately EUR 3.5 million from the IPO. The objective of the Offering is primarily to enable the Company to raise funds to complete ARTEBONE®’s ongoing application processes for the CE mark and FDA approval, begin commercial production and the commercialisation of the product. BBS market value is 20,1 mil. EUR

- Other similar size medical research companies recently listed on Nasdaq are Nexstim valued at 20,1 million EUR, Herantis Pharma valued at 30,4 million EUR and previously listed Immunovia valued at 3,1 billion SEK. These have a narrower potential market reach and are predicting sales in the coming years. 

- A more recent peer group study of comparables shows a peer group valuation starting from $521 million with an average peer group valuation of $2.6 billion and a geometrical mean of $1.5 billion. Peer group sample size was 52. The sample includes companies like UpHealth, Eargo, Butterfly Network., Dialogue Health Technologies, CompuGroup Medical SE & Co KgaA, Avanos Medical, Mentice AB, Life Semantics, Viemed Healthcare, Zynex, DarioHealth, Soliton, Semler Scientific, Global Health, Reliq Health Technologies,  Clover Health Investments, InnovAge Holding, Treatment International, Alignment Healthcare, Think Research, Aveanna Healthcare Holdings, Welby, Computer Programs and Systems.

Cashflows around hospital beds only with the Software medicine.

The formula assumes 500 beds per hospital. The number of beds in hospitals varies. EU- 28 has 2,6 million available hospital beds. A very crude calculation estimate for the patient only can provide savings of +30, - € per example patient. For one institution with 500 beds and 10 patients per month/bed implemented for everyone suitable, would equal 1,8 million yearly (Using Gordons growth formula this equals a value of 60 million). To this can be added the additional 10 -100 € million, for other cost reductions, from a valuation perspective per institution.

Area of operation

Europe, USA and Asia.

Hospitals*, geriatric and home care institutions mainly.

Hospital numbers by top countries:

China 69.105, India 15.067, Vietnam 12.500, Nigeria 11.588, Russia 11.200, Japan 9.143, Europe 7.154, Egypt 6.446, Brazil 6410, USA 6.097

Hospital beds per 1000 people Japan 13,4 beds per 1000, Germany 8,27 beds (E.g. translating in Germany with 80 mil. people to 661.600 beds.) Austria 7,65, Poland 6,55, France 6,37, Belgium 6,31, Finland 5,52, Australia 3,77, Italy 3,42, US 3,26, Spain 3,05, UK 2,95, Sweden 2,75 Canada 2,71. http://ec.europa.eu/eurostat/statistics-explained/index.php/Healthcare_resource_statistics_-_beds

Worldwide prescription drug sales

Worldwide prescription drug sales expected to reach almost one trillion dollars by 2020. EvaluatePharma® finds that the market for prescription drugs, based on consensus forecasts for the leading 500 pharmaceutical and biotechnology companies, will grow by a robust 4.8% per year (CAGR) to reach $987bn by 2020.

Competitors

To provide the functions securely in even a rapid manner a Software medicine is needed. These criteria are not filled by the other alternatives. In addition, it is good to stress the importance of the specific functions for the benefits to materialise as the research points out.

SWOT

Company strengths

Small, light and low cost with easily sellable product that scales everywhere and is not dependent on place of use. Proven product, researched benefits and uses at standardized institutions. Product functions as called for and depicted by research for maximum benefit by leading professionals internationally. Potential customer numbers are rising, and product tackles problems and issues depicted in global research. Product is suitable everywhere in the world. The product reduces costs and can be used to bring in more revenue for the customer.

Company weaknesses

Low cost strategy and possible resistance from competitors and institutions toward a software medicine product.

Company opportunities

Bettering health. Tackling depicted problems and benefits in hospitals, geriatric care, home care and psychiatric care with research proven global functions in institutions in the world. Cutting costs and generating added revenue for the customer institutions as well.

Company threats

There are generally only four types of risk:

That sales are low: The product uniqueness and function tackling and solving recognized problems in the world aid in approaching the countless suitable institutions. As costs are an issue many times at institutions The device low cost and automatic function go a long way coupled with the possibility to generate revenue. (Many other part solutions require additional staff and a larger framework with many added tasks although they offer little advantage.) This is a clear strain and cost source that the device is not burdened with.)

That margins are low: The products cost structure is designed to be cost efficient especially as income levels in different parts of the world can vary even greatly. Comparing EU or the US and China for instance where average medicine spend per person and month can vary greatly.

That costs are high: The product and its benefits can be easily, and cost effectively presented. It is easy to use, deliver, and set up. From that perspective costs should stay low. The product is not free, and the margin can move to accommodate different circumstances.

That a major operational problem occurs: From a product and software perspective this is not the case as it is tested and will be tested and built with standard and well proven methods for every day use. A malfunction can easily be fixed and is not hazardous. This is the case on all major and developed markets.

Self-assessment

Solid product based upon broad and solid research bettering health, tackling present issues and problems all over the world. A true software medicine product with little direct suitable competition.

Research references

E.g. a research plan references 240 reputable researches, studies, book studies, case studies and institutions proving the positive effect of the software medicine functions, the need for the device functions and also what the device fixes in todays and tomorrows institutions. This research is performed in Finland, Sweden, Europe, the US, Australia, Asia, the whole world as stated earlier the worlds health institutions function very similarly (mostly exactly the same), we suffer sicknesses in the same way no matter where we are and mend in the same way.

To this can of course be added the support from the university hospital head of research and other members of staff in Finland, the geriatric team and other professionals approached in the matter.

And the device does, treats and solves issues depicted by research exactly.

One of the top hospitals in the world (US) has posted a RFI for 100-500K for one part of the devices functions.

Its function has improved quality of life by 15% over 6 months. Its function has increased survival over 1 year by 6,5%.

Software Medicine functions after stroke not only enhances behavioural recovery, but also induces fine-grained neuroanatomical changes in the recovering brain.

Its functions offer psychological and physiological relief in many areas suiting wide use at stated places and institutions.

Functions of the device rigorously follow vast proven research governed by the FDA, EMA and WMA. Meaning research plan, method and results are governed by law. Vastly researched and proven product functions by top researchers at top institutions globally to find what works and what is called for to bring better health.

For example, most doctors in Britain see between 1 and 5 patients a day due to isolation. The software medicine is effective for this in its environment. Britain has appointed a minister for loneliness because health implications and costs are staggering due to loneliness.

Funding:

The effect of the functions of the product have been established in vast global clinical trials. Vast global research has established the need for the products functions at institutions and in health care globally. Also, by the very top professionals in Finland and Scandinavia. The device is MD1 and Class 1 in the US. The Japanese market follows with the CE-mark requiring a translation. China and other parts of the world further down the road.

---

Contact Strategies